Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review
-
Published:2024-01-06
Issue:2
Volume:25
Page:752
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Watanabe Kiyotaka1ORCID, Seki Nobuhiko1
Affiliation:
1. Department of Medicine, School of Medicine, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
Abstract
DNA-targeted drugs constitute a specialized category of pharmaceuticals developed for cancer treatment, directly influencing various cellular processes involving DNA. These drugs aim to enhance treatment efficacy and minimize side effects by specifically targeting molecules or pathways crucial to cancer growth. Unlike conventional chemotherapeutic drugs, recent discoveries have yielded DNA-targeted agents with improved effectiveness, and a new generation is anticipated to be even more specific and potent. The sequencing of the human genome in 2001 marked a transformative milestone, contributing significantly to the advancement of targeted therapy and precision medicine. Anticipated progress in precision medicine is closely tied to the continuous development in the exploration of synthetic lethality, DNA repair, and expression regulatory mechanisms, including epigenetic modifications. The integration of technologies like circulating tumor DNA (ctDNA) analysis further enhances our ability to elucidate crucial regulatory factors, promising a more effective era of precision medicine. The combination of genomic knowledge and technological progress has led to a surge in clinical trials focusing on precision medicine. These trials utilize biomarkers for identifying genetic alterations, molecular profiling for potential therapeutic targets, and tailored cancer treatments addressing multiple genetic changes. The evolving landscape of genomics has prompted a paradigm shift from tumor-centric to individualized, genome-directed treatments based on biomarker analysis for each patient. The current treatment strategy involves identifying target genes or pathways, exploring drugs affecting these targets, and predicting adverse events. This review highlights strategies incorporating DNA-targeted drugs, such as PARP inhibitors, SLFN11, methylguanine methyltransferase (MGMT), and ATR kinase.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference89 articles.
1. DNA and its associated processes as targets for cancer therapy;Hurley;Nat. Rev. Cancer,2002 2. Initial sequencing and analysis of the human genome;Lander;Nature,2001 3. Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, B.E., Ladekarl, M., Haslund, C.A., Harsløf, L., Belcaid, L., and Gehl, J. (2023). ProTarget: A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling—A national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer, 23. 4. Genome-guided discovery of cancer therapeutic targets;Konda;Cell Rep.,2023 5. Langenberg, K.P.S., Looze, E.J., and Molenaar, J.J. (2021). The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development. Cancers, 13.
|
|